Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase

(2014) Li-Fan Zeng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies

(2013) B. Yu et al.   MOLECULAR CANCER THERAPEUTICS

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT

(2012) R. S. Mali et al.   BLOOD

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Endogenous viruses: insights into viral evolution and impact on host biology

(2012) Cédric Feschotte et al.   NATURE REVIEWS GENETICS

Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell pool

(2011) H. H. Zhu et al.   BLOOD

Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells

(2011) G. Chan et al.   BLOOD

The dynamic interplay between a PTK (Kit) and a PTP (Shp2) in hematopoietic stem and progenitor cells

(2011) Helen He Zhu et al.   CELL CYCLE

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

(2009) G. Chan et al.   BLOOD

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group

(2009) A Larson Gedman et al.   LEUKEMIA

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL